Printed From:

Lantus® was evaluated for 52 weeks in insulin-naive adult patients with type 2 diabetes on OADs

A1C decreased by

1.5%

in the Lantus® and insulin detemir treatment groups and was comparable among groups after 52 weeks (7.1% for Lantus® and 7.2% for insulin detemir)

52% of participants in the study achieved A1C ≤7%

100% of Lantus® patients were dosed once a day throughout the study

Safety results

Study Design

An open-label, parallel-group, noninferiority trial of 582 insulin-naive patients with type 2 diabetes. Patients were randomized 1:1 to receive Lantus® (n=291) or insulin detemir (n=291) once daily (in the evening) as add-on therapy to oral glucose-lowering drugs. Both insulins were titrated to an FPG target of ≤108 mg/dL. An additional morning insulin dose of insulin detemir was allowed if pre-dinner PG was >126 mg/dL, but only if pre-breakfast PG was <126 mg/dL or nocturnal hypoglycemia (major episode or PG ≤72 mg/dL) precluded achievement of the FPG target. Participants were eligible if A1C ranged from 7.5% to 10%. Primary endpoint was change in A1C at end of treatment period.

*Eligibility Restrictions

This offer is not valid for prescriptions covered by or submitted for reimbursement under Medicare, Medicaid, VA, DOD, TRICARE, or similar federal or state programs including any state pharmaceutical assistance program. Important to note that if you have an Affordable Care (Health Care Exchange) plan, you may still be qualified to receive and use this savings card. Please note: the Federal Employees Health Benefits (FEHB) Program is not a federal or state government health care program for purposes of the savings program. Void where prohibited by law.

Savings may vary depending on patients' out-of-pocket costs. Upon registration, patients receive all program details. Sanofi US reserves the right to change the maximum cap amount, rescind, revoke, or amend the program without notice.

Offer Terms for Lantus $0 Co-pay Savings Card

For the duration of the program, the Savings Card offers a $0 copay with a maximum savings up to $600 per box for prescriptions covered by private or commercial insurance. This offer is valid for up to 3 boxes per prescription.

Offer Terms for Insulins Valyou Savings Program ($99)

Sanofi insulins included in this program are: LANTUS® (insulin glargine injection) 100 Units/mL, TOUJEO® (insulin glargine injection) 300 Units/mL, ADMELOG® (insulin lispro injection) and APIDRA® (insulin glulisine injection) 100 Units/mL

This offer is not valid for prescriptions covered by commercial / private insurance. Only people without prescription medication insurance can apply for this offer. For the duration of the program, eligible patients will pay $99 for up to 10 vials or packs of pens per fill. Offer is valid for one fill per month. In order for you to pay $99 per month, you must fill all your Sanofi Insulin prescriptions at the same time, together each month. When using the Insulins Valyou Savings Card, prices are guaranteed for 12 consecutive monthly fills. This offer is not valid for the Max SoloStar pen. The Insulins Valyou Savings Program applies to the cost of medication. There are other relevant costs associated with overall treatment.